Selected articles
Articles for label Filipenský Petr are displayed.. Show all articles
Is radium‑223 a universal drug of bone metastasis in castration‑resistant prostate cancer?
03/2018 MUDr. Jana Katolická, Ph.D.; MUDr. Petr Filipenský, Ph.D.
Bone metastases in prostate cancer are a major cause of pain and bone complications. Radium-223 treatment of patients with bone metastasis in castration-resistant prostate cancer proved to be beneficial in prolonging overall survival. Administration of 5-6 doses of radium-223 compared to 1-4 doses is associated with a significantly longer overall survival. The most common haematological adverse event induced treatment is anemia and thrombocytopenia.
ENTIRE ARTICLE
Bone metastases in prostate cancer are a major cause of pain and bone complications. Radium-223 treatment of patients with bone metastasis in castration-resistant prostate cancer proved to be beneficial in prolonging overall survival. Administration of 5-6 doses of radium-223 compared to 1-4 doses is associated with a significantly longer overall survival. The most common haematological adverse event induced treatment is anemia and thrombocytopenia.